SciSparc (SciSparc) Common Stock : $64.53 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is SciSparc Common Stock?

SciSparc's quarterly common stock increased from Dec. 2022 ($58.59 Mil) to Jun. 2023 ($58.90 Mil) and increased from Jun. 2023 ($58.90 Mil) to Dec. 2023 ($64.53 Mil).

SciSparc's annual common stock increased from Dec. 2021 ($58.54 Mil) to Dec. 2022 ($58.59 Mil) and increased from Dec. 2022 ($58.59 Mil) to Dec. 2023 ($64.53 Mil).

SciSparc Common Stock Historical Data

The historical data trend for SciSparc's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciSparc Common Stock Chart

SciSparc Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

45.64

49.04

58.54

58.59

64.53

SciSparc Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															58.54	58.55	58.59	58.90	64.53

SciSparc Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

SciSparc (SciSparc) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SPRC:USA

Address

20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916

Website

https://www.scisparc.com

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.